Clinical trial / 2005
Urtica dioica improved symptoms, urinary flow rates, and residual volume, and modestly reduced prostate size in men with benign prostatic hyperplasia.
A 6-month randomized, double-blind, placebo-controlled trial with a partial crossover evaluated Urtica dioica versus placebo in 620 patients with benign prostatic hyperplasia, followed up to 18 months. At 6 months, 81% (232/287) of patients in the Urtica dioica group reported improved symptoms compared with 16% (43/271) receiving placebo (P < 0.001). IPSS decreased from 19.8 to 11.8 with Urtica dioica versus 19.2 to 17.7 with placebo (P = 0.002), while peak flow rates improved by 8.2 mL/s versus 3.4 mL/s (P < 0.05). Postvoid residual volume decreased from 73 to 36 mL (P < 0.05) and prostate size decreased modestly from 40.1 to 36.3 cc (P < 0.001) with Urtica dioica, without changes in PSA or testosterone and with no identified side effects.
- Study type
- Randomized, double-blind, placebo-controlled, partial crossover trial
- Who was studied
- 620 patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia
- What was measured
- IPSS, Qmax, postvoid residual urine volume, serum PSA, testosterone, and prostate size
THE PAPER
Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study.
Safarinejad MR. J Herb Pharmacother, 2005.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.